V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Denali Therapeutics Executive Compensation (FY25)

DNLI · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): June 4, 2026
207 figures on this page: 200 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
Chief executive, fiscal 2025
◇
Ryan Watts
Latest say-on-pay support
=
June 3, 2026
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Ryan Watts: $6,557,662 → $4,751,515 (27.5% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Denali Therapeutics' chief executive and what were they paid?
Ryan Watts was paid $4,751,515 in total compensation as President and Chief Executive Officer for fiscal 2025. Watts' total moved 27.5% lower from the $6,557,662 reported for fiscal 2024.
What was Denali Therapeutics' say-on-pay result?
For fiscal 2025, the say-on-pay proposal drew 93.8% support at the meeting held June 3, 2026.
Which companies are in Denali Therapeutics' peer group?
The disclosed peer group includes Agios Pharmaceuticals, Alector Therapeutics, Arcus Biosciences, Avidity Biosciences and Axsome Therapeutics, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ryan Watts
President and Chief Executive Officer
◇◇◇◇——◇◇
Alexander Schuth
Chief Operating and Financial Officer and Secretary
◇◇◇◇——◇◇
Carole Ho
Chief Medical Officer and Head of Development (until November 14, 2025)
◇◇◇◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ryan Watts
President and Chief Executive Officer
◇◇◇◇——◇◇
Alexander Schuth
Chief Operating and Financial Officer and Secretary
◇◇◇◇——◇◇
Carole Ho
Chief Medical Officer and Head of Development (until November 14, 2025)
◇◇◇◇——◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ryan Watts
President and Chief Executive Officer
◇◇◇◇——◇◇
Alexander Schuth
Chief Operating and Financial Officer and Secretary
◇◇◇◇——◇◇
Carole Ho
Chief Medical Officer and Head of Development (until November 14, 2025)
◇—◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Alexander O. SchuthOPTION◇——◇—◇◇
Alexander O. SchuthOPTION◇——◇—◇◇
Carole HoOPTION◇——◇—◇◇
Carole HoOPTION◇————◇◇
Ryan J. WattsOPTION◇——◇—◇◇
Ryan J. WattsOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Ryan WattsRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇01/03/2035
Option◇—◇01/03/2033
RSU◇◇——
Option◇—◇01/03/2032
Option◇—◇01/03/2034
Carole HoRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇01/03/2034
RSU◇◇——
RSU◇◇——
Option◇—◇01/03/2033
Option◇—◇01/03/2032
Option◇—◇01/03/2035
Alexander SchuthRSU◇◇——
RSU◇◇——
Option◇—◇01/03/2035
RSU◇◇——
Option◇—◇01/03/2032
RSU◇◇——
RSU◇◇——
Option◇—◇01/03/2033
Option◇—◇01/03/2034
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Julian C. Baker
Board chair
◇◇◇———◇
Tim Van Hauwermeiren
◇◇◇———◇
Peter Klein
◇◇◇———◇
Jay Flatley
◇◇◇———◇
David Schenkein, M.D
◇◇◇———◇
Nancy A. Thornberry
◇◇◇———◇
Jennifer Cook
◇◇◇———◇
Steve E. Krognes
◇◇◇———◇
Marc Tessier-Lavigne, Ph.D
◇◇◇———◇
Vicki Sato, Ph.D
◇◇————◇
Erik Harris
◇—————◇
Ryan J. Watts, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options and RSUs.
Stock ownership guideline: 3x base annual cash retainer

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Agios Pharmaceuticals AGIO
  • Alector Therapeutics ALEC
  • Arcus Biosciences RCUS
  • Avidity Biosciences RNAM
  • Axsome Therapeutics AXSM
  • Beam Therapeutics BEAM
  • Biohaven BHVN
  • Blueprint Medicines BPMC
  • BridgeBio Pharma BBIO
  • CRISPR Therapeutics CRSP
  • Cytokinetics CYTK
  • Dyne Therapeutics DYN
  • Intellia Therapeutics NTLA
  • Intra-Cellular Therapies ITCI
  • Iovance Biotherapeutics IOVA
  • Neumora Therapeutics NMRA
  • Prothena Corporation PRTA
  • REGENXBIO RGNX
  • Revolution Medicines RVMD
  • Sage Therapeutics SAGE
  • Ultragenyx Pharmaceutical RARE
  • Vaxcyte PCVX
  • Vir Biotechnology VIR

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 3, 2026=◇◇◇
2024June 3, 2025=◇◇◇
2023May 31, 2024=◇◇◇
2022June 1, 2023=◇◇◇
2021June 2, 2022=◇◇◇
2020June 2, 2021=◇◇◇
2019June 3, 2020=◇◇◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Denali Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Denali Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Denali Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Denali Therapeutics' disclosed peer group is defensible, who names Denali Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
207 figures on this page: 200 cited to the filing that reported them, 7 calculated from figures it prints.
200 cited to the filing
7 calculated from the filing

Documents cited

  1. 0001714899-26-000074
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001714899-26-000054
    2025 Director Compensation · EXECUTIVE COMPENSATION · Outstanding Equity Awards as of 2025 Fiscal Year End · Summary Compensation Table For Fiscal
  3. 0001714899-25-000128
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001714899-25-000087
    DIRECTOR COMPENSATION · Summary Compensation Table For Fiscal
  5. 0001714899-24-000125
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001714899-24-000110
    Summary Compensation Table For Fiscal
  7. 0001714899-23-000079
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001714899-22-000082
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001714899-21-000058
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001714899-20-000060
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Denali Therapeutics executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/DNLI (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Denali Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Denali Therapeutics discloses

The companies named in DNLI's own disclosed peer group.

Agios PharmaceuticalsArcus BiosciencesBeam TherapeuticsBiohavenBridgeBio PharmaCRISPR TherapeuticsCytokineticsDyne TherapeuticsREGENXBIOUltragenyx PharmaceuticalVaxcyte

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy